The presentation will cover the biological, experimental medicine and translation neuroscience thinking and progress behind the evolution of CGRP directed therapies.

With the advent of oral and parenteral CGRP antagonists, are the older "traditional" preventive and acute medications still valuable? This presentation will explore clinical trial data, including comparative data, situations in which older medications may be beneficial or harmful, and financial considerations as we to navigate our expanding migraine treatment landscape.

This presentation will describe new therapeutic targets for headache disorders that are being developed based upon new understanding of fundamental mechanisms of headache. Therapeutic targets to be discussed include the hypothalamus, upper cervical nerves, adenosine receptors, amylin, pituitary adenylate cyclase activating peptide (PACAP), and glutamate and its receptors.